Form 8-K · Current report
AbbVie 8-K, filed Jul 31, 2026
- Filed
- CIK
- 0001551152
- Accession no.
- 0001551152-26-000023
Summary
AbbVie reported second-quarter 2026 net revenues of $16.990 billion and GAAP diluted EPS of $2.03, and said it agreed to acquire Apogee Therapeutics at a total equity value of approximately $10.9 billion. AbbVie also updated its 2026 adjusted diluted EPS guidance to $13.87–$14.07 and disclosed FDA and European Commission approvals involving Skyrizi, Rinvoq, Aquipta, Decnupaz and Venclyxto.
Key points
- AbbVie reported second-quarter 2026 net revenues of $16.990 billion, up 10.2% on a reported basis, with GAAP diluted EPS of $2.03 and adjusted diluted EPS of $3.65.
- Immunology portfolio net revenues were $8.786 billion, including Skyrizi at $5.505 billion, Rinvoq at $2.525 billion and Humira at $756 million.
- AbbVie said it agreed to acquire Apogee Therapeutics and its clinical-stage immunology pipeline, valuing Apogee at about $10.9 billion in total equity value, with the deal expected to close in the third quarter of 2026.
- AbbVie updated its 2026 adjusted diluted EPS guidance range to $13.87–$14.07, including a $0.14 per share dilutive impact from the proposed Apogee acquisition and a $0.58 per share unfavorable impact from acquired IPR&D and milestones expense year-to-date through the second quarter.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition On July 31, 2026, AbbVie Inc. issued a press release announcing financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference. Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Exhibit 99.1 Press Release dated July 31, 2026 (furnished pursuant to Item 2.02). 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.